Circulating miRNA–Protein Signatures Predict Outcomes in Pediatric Dilated Cardiomyopathy

<b>What New Question Does This Study Raise?</b> Can integrated circulating miRNA-protein signatures identify biologically distinct trajectories of recovery versus progression in children with dilated cardiomyopathy?Do circulating molecular profiles reflect underlying disease mechanisms that determine divergent clinical outcomes in pediatric DCM? <b>What Question Should Be Addressed Next?</b> Do the pathways identified by integrated miRNA-protein analysis (fibrosis, remodeling, and inflammation) play causal roles in determining recovery versus progression?Can multi-omic biomarkers be incorporated into prospective studies to improve early risk stratification and guide clinical management?